Diagnosis of maxillofacial tumor with L-3-[18F]-fluoro-α- methyltyrosine (FMT) PET: A comparative study with FDG-PET

Annals of Nuclear Medicine

Volumn 21, Issue 2, 2007, Pages 129-135

  Miyakubo, Mitsuyuki ^a   Oriuchi, Noboru ^a,b   Tsushima, Yoshito ^a   Higuchi, Tetsuya ^a   Koyama, Keiko ^a   Arai, Kiyokazu ^a   Paudyal, Bishnuhari ^a   Iida, Yasuhiko ^a   Hanaoka, Hirofumi ^a   Ishikita, Tomohiro ^a   Nakasone, Yoshiki ^a   Negishi, Akihide ^a   Mogi, Kenji ^a   Endo, Keigo ^a  

^a GUNMA UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Maxillofacial tumor; PET

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE F 18; LEVO 3 FLUORO ALPHA METHYLYTYROSINE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MAXILLOFACIAL CANCER; MAXILLOFACIAL DISORDER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; ROC CURVE; TUMOR DIAGNOSIS;

EID: 33947634040     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033991     Document Type: Article

References (24)

1. Rege SD, Chaiken L, Hoh CK, Choi Y, Lufkin R, Anzai Y, et al. Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: quantitation with PET. Radiology 1993; 189: 807-812.
2. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33: 1972-1980.
3. Inoue T, Koyama K, Oriuchi N, Alyafei S, Yuan Z, Suzuki H, et al. Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG-preliminary study. Radiology 2001; 220: 54-62.
4. Watanabe H, Inoue T, Shinozaki T, Yanagawa T, Ahmed AR, Tomiyoshi K, et al. PET imaging of musculoskeletal tumours with fluorine-18 alpha- methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET. Eur J Nucl Med 2000; 27: 1509-1517.
5. 18F alpha-methyl tyrosine positron-emission tomography. Neuroradiology 2003; 45: 700-707.
6. Sobin LH, Wittekind C, eds. Union Against Cancer - TNM Classification of Malignant Tumours. 6th ed. New York; John Wiley-Liss Incorporated, 2002.
7. 18F-alpha-methyltyrosine using a separation and purification system. Nucl Med Commun 1997; 18: 169-175.
8. Ido T, Wan CN, Fowler JS, Wolf AP. Fluorination with molecular fluorine. A convenient synthesis of 2-deoxy-2-fluoro-D-glucose. J Org Chem 1977; 42: 2341-2342.
9. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27: 235-238.
10. Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4th ed. Oxford; Blackwell Science, 2002.
11. Metz CE. ROC methodology in radiologic imaging. Invest Radiol 1986; 21: 720-733.
12. 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol 2006; 11: 286-296.
13. Oriuchi N, Higuchi T, Ishikita T, Miyakubo M, Hanaoka H, Iida Y, et al. Present role and future prospect of positron emission tomography in clinical oncology. Cancer Sci 2006; 97: 1291-1297.
14. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. J Nucl Med 2005; 46: 1136-1143.
15. Nakasone Y, Inoue T, Oriuchi N, Takeuchi K, Negishi A, Endo K, et al. The role of whole-body FDG-PET in preoperative assessment of tumor staging in oral cancers. Ann Nucl Med 2001; 15: 505-512.
16. 18F-FDG PET. Ann Nucl Med 2004; 18: 409-417.
17. 18F-FDG PET. J Nucl Med 2004; 45: 226-231.
18. Geets X, Daisne JF, Gregoire V, Hamoir M, Lonneux M. Role of 11-C-methionine positron emission tomography for the delineation of the tumor volume in pharyngo-laryngeal squamous cell carcinoma: comparison with FDG-PET and CT. Radiother Oncol 2004; 71: 267-273.
19. 18F-FDG PET for maxillofacial tumor; comparative immunohistopathological analysis with cellular proliferation (Ki-67) and amino-acid transporter expression (LAT-1). [abstract] J Nucl Med 2006; 47 (Suppl): p467.
20. 125I-iodo-alpha-methyl-L-tyrosine membrane transport in human L-type amino acid transporters. J Nucl Med 2003; 44: 244-246.
21. Lahoutte T, Caveliers V, Camargo SM, Franca R, Ramadan T, Veljkovic E, et al. SPECT and PET amino acid tracer influx via system L (h4F2hc-hLAT1) and its transstimulation. J Nucl Med 2004; 45: 1591-1596.
22. 18F]Fluoroethyl)-L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Imaging 2002; 29: 1039-1046.
23. 18F-FDG PET and CT in patients with head and neck cancer. J Nucl Med 2006; 47: 256-261.
24. Alvi A, Johnson JT. Development of distant metastasis after treatment of advanced-stage head and neck cancer. Head Neck 1997; 19: 500-505.